Home Cart Sign in  
Chemical Structure| 110448-33-4 Chemical Structure| 110448-33-4

Structure of ML-7 HCl
CAS No.: 110448-33-4

Chemical Structure| 110448-33-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML-7 HCl is a multiple-target inhibitor of MLCK with Ki value of 300 nM, PKA with 21μM, and PKC of 42 μM.

Synonyms: ML-7 (hydrochloride); ML-7 hydrochloride; ML-7

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML-7 HCl

CAS No. :110448-33-4
Formula : C15H18ClIN2O2S
M.W : 452.74
SMILES Code : Cl.IC1=CC=CC2=C1C=CC=C2S(=O)(=O)N1CCCNCC1
Synonyms :
ML-7 (hydrochloride); ML-7 hydrochloride; ML-7
MDL No. :MFCD00065524
InChI Key :KDDALCDYHZIZMH-UHFFFAOYSA-N
Pubchem ID :9803932

Safety of ML-7 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ML-7 HCl

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PDGFRA D842V GIST cells, GIST T1 cells 4 μM to 40 μM 24 h, 48 h ML-7 was used to induce apoptosis and disrupt actin filaments, showing an additive effect in combination with avapritinib in reducing cell viability. PMC10239357
Klebsiella pneumoniae 32-128 mg/mL 1 h ML-7 increases the efficacy of tigecycline against resistant strains by inhibiting efflux pumps and reducing ATP levels. PMC8766836
Caco-2 cells 25 µM 6 h to mitigate down-regulation of mucosa-related protein expression. PMC11171766

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Patient-derived xenograft (PDX) model of PDGFRA D842V-mutant GIST Gavage 10 mg/kg Daily for 2 weeks The combined therapy with ML-7 improved the anti-tumor effects of low-dose avapritinib in vivo. PMC10239357

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.21mL

0.44mL

0.22mL

11.04mL

2.21mL

1.10mL

22.09mL

4.42mL

2.21mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories